Bentley Pharmaceuticals to Present at the Annual UBS Global Life Sciences Conference

EXETER, N.H., Sept. 20 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. , a specialty pharmaceutical company, announced today that John A. Sedor, president of the Company, will be presenting at the UBS Global Life Sciences Conference at the Grand Hyatt in New York, NY. The presentation is scheduled for Wednesday, September 27, 2006 at 1:30 p.m. (EDT).

The presentation will be broadcast live over the internet and may be accessed via the Company's website, http://www.bentleypharm.com/. In addition, a replay of the presentation will be available beginning three hours after the presentation time and will remain available on the Company's website through October 30, 2006.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiary, Laboratorios Belmac, and markets these pharmaceutical products through its subsidiaries, Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley's web site at http://www.bentleypharm.com/.

Contact: Bentley Pharmaceuticals, Inc. Jean DeRoche 603.658.6136